Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02140021 · ClinicalTrials.gov registry record · NA
Biospecimen Collection and Testing for the Prevalence of Anal Dysplasia and Anal Cancer in Patients With Cervical, Vaginal and Vulvar Dysplasia and Cancer
A NA study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- NA
- Development phase
- 409
- Enrollment target
NCT02140021: Clinical Trial NA study, sponsored by M.D. Anderson Cancer Center.
NCT02140021 is a NA study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 409 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02140021, a NA study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 409 participants
- Enrollment target
Study Summary
This trial studies the prevalence of anal dysplasia and anal cancer in patients with cervical, vaginal, and vulvar dysplasia and cancer. Studying samples collected from patients in the laboratory may help doctors learn more about the human papillomavirus and how often anal cancer occurs in patients with cervix, vagina, or vulvar cancer.
Interventions
- PROCEDURE Biospecimen Collection
- OTHER Laboratory Biomarker Analysis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 409 participants |
| Start Date | 2014-10-27 |
| Est. Completion | 2025-07-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02140021
The ClinicalTrials.gov registry entry for NCT02140021 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 409 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Biospecimen Collection is the first listed.
NCT02140021 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02140021 about?
NCT02140021 is a clinical study titled "Biospecimen Collection and Testing for the Prevalence of Anal Dysplasia and Anal Cancer in Patients With Cervical, Vaginal and Vulvar Dysplasia and Cancer". This trial studies the prevalence of anal dysplasia and anal cancer in patients with cervical, vaginal, and vulvar dysplasia and cancer. Studying samples collected from patients in the laboratory may help doctors learn more about the human papillomavirus and how often anal cancer occurs in patients ...
What is the current status of trial NCT02140021?
This trial is currently terminated. It is a NA study. The enrollment target is 409 participants. The study started on 2014-10-27. Estimated completion is 2025-07-08.
What interventions are being tested in trial NCT02140021?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Laboratory Biomarker Analysis (OTHER).
Who is sponsoring clinical trial NCT02140021?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.